Comparison · NCT02024087-sae
Dalantercept 0.4 mg/kg Plus Sorafenib vs Dalantercept 0.6 mg/kg Plus Sorafenib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dalantercept 0.4 mg/kg Plus Sorafenib vs Dalantercept 0.6 mg/kg Plus Sorafenib: serious adverse events. Trial comparisons, record NCT02024087-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02024087-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.375 | 0.185 | 0.614 | wilson | |
| Risk in group 2 | 0.8 | 0.376 | 0.964 | wilson | |
| Risk difference, group 1 minus group 2 | -0.425 | -0.676 | 0.0619 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.469 | 0.217 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | 0.15 | 0.0134 | 1.68 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Dalantercept 0.4 mg/kg Plus Sorafenib than on Dalantercept 0.6 mg/kg Plus Sorafenib | 2.35 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dalantercept 0.4 mg/kg Plus Sorafenib | Dalantercept plus sorafenib: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily. | 6 | 16 | EG000 |
| Group 2 | Dalantercept 0.6 mg/kg Plus Sorafenib | Dalantercept plus sorafenib: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily. | 4 | 5 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collection from the date of first patient enrollment to the end-of study visit (approximately 20 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- NCT number
- NCT02024087
- Phases
- PHASE1, PHASE2
- Conditions
- Advanced Adult Hepatocellular Carcinoma
- Interventions
- Dalantercept plus sorafenib
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Results first posted
- 2020-12-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02024087?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02024087-sae